Skip to content
Makers Laboratories logo

Makers Laboratories

MAKERSL NSE
₹189.01 down 0.17 (0.09%)
Market Cap
₹112 Cr

Makers Laboratories (MAKERSL) share price was ₹189.18 at the 28 Oct 2026 close; market capitalisation ₹112 Cr; sector Healthcare. The share price rose 45.5% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue rose 22.3% year on year to ₹42.8 Cr and net profit was ₹4.59 Cr, against ₹1.29 Cr a year earlier (compared with Jun 2025). Promoters held 61.27% of Makers Laboratories in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 58/100 (Good) as of 28 Oct 2026.

Close 28 Oct 2026 ₹189.18 +63.88 +50.98% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹112 Cr
EBITDA
₹16.40 Cr
Return on Equity
6.42%
Debt to Equity
0.12
Book Value
₹123.59
EPS (TTM)
—
52W High
₹236.00
52W Low
₹109.00

Price-based figures as of 29 Oct 2026, 10:22 IST · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,766.7035.054,23,891 Cr5.070.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,655.0087.632,56,310 Cr15.290.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,610.5072.381,75,369 Cr9.540.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,188.00108.101,18,220 Cr22.310.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,181.3026.291,17,835 Cr4.350.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,338.7034.671,11,739 Cr2.880.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,364.8032.701,10,257 Cr3.120.96%11.21%14.88%28,589 Cr3,356 Cr
Makers Laboratories (this company)
₹189.01—112 Cr1.530.00%6.42%8.99%150 Cr11 Cr
Median 8 companies₹1,565.7535.051,18,028 Cr4.710.47%12.98%16.41%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company. 1 company is not shown because they are not listed on an exchange we cover.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

58 Good
Overall score

Data confidence 100/100

Category scores

Quality Good 56
Returns, margins, earnings quality 22% weight
Valuation Average 55
Cheap vs sector & own history 24% weight
Growth Good 63
Sales & profit trajectory 9% weight
Financial Health Good 59
Solvency, leverage, coverage 9% weight
Momentum Strong 90
Trend strength, vol-adjusted 12% weight
Ownership Average 50
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company has delivered good profit growth of 49.3% CAGR over last 5 years
  • Debtor days have improved from 68.8 to 51.6 days.

Weaknesses

2
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of -2.05% over last 3 years.

Technical Indicators

Oscillators

Bullish

Bearish
1
Neutral
6
Bullish
2

Overall

Bullish

Bearish
5
Neutral
6
Bullish
8

Moving Averages

Bullish

Bearish
4
Neutral
0
Bullish
6

Growth Rate

Revenue Growth
7.32% lower than 3Y

change over 1 year

Net Income Growth
-27.52% lower than 3Y

change over 1 year

Cash Flow Change
450%

change over 1 year

EBITDA Margin Change
-24.35%

change over 1 year Operating margin 16.27% · Jun 2026

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
25.01
25.06
26.51
27.81
29.59
29.57
27.69
33.9
35
34.17
35.67
35.75
42.77
Expenses
25.15
24.86
26.31
26.95
27.78
27.38
26.38
30.81
31.99
31.89
31.51
30.47
35.81
Operating Profit
-0.14
0.2
0.2
0.86
1.81
2.19
1.31
3.09
3.01
2.28
4.16
5.28
6.96
OPM %
-0.56%
0.8%
0.75%
3.09%
6.12%
7.41%
4.73%
9.12%
8.6%
6.67%
11.66%
14.77%
16.27%
Other Income
0.25
0.41
0.37
0.43
-0.51
10.63
0.87
0.1
0.27
0.36
0.33
0.76
0.61
Interest
0.41
0.49
0.53
0.52
0.49
0.43
0.19
0.18
0.18
0.22
0.2
0.17
0.15
Depreciation
1.11
1.13
1.16
1.15
1.28
1.29
1.31
0.9
1.12
1.13
1.14
1.13
1.13
PBT
-1.41
-1.01
-1.12
-0.38
-0.47
11.1
0.68
2.11
1.98
1.29
3.15
4.74
6.29
Tax %
18.44%
10.89%
-4.46%
152.63%
48.94%
11.98%
60.29%
24.64%
34.85%
42.64%
27.94%
24.89%
27.03%
Net Profit
-1.66
-1.13
-1.06
-0.97
-0.7
9.76
0.27
1.58
1.29
0.74
2.27
3.56
4.59
EPS (₹)
-3.56
-2.27
-2.61
-2.19
-1.66
14.95
-0.51
-0.08
0.75
-0.2
1.59
1.85
2.54
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
69
127
101
104
121
141
148
Expenses
60
108
98
103
112
126
130
Operating Profit
8
19
3
1
9
15
19
OPM %
12%
15%
3.3%
1.1%
7%
11%
13%
Other Income
1
3
2
2
11
2
2
Interest
2
2
2
2
1
1
1
Depreciation
5
4
4
5
5
5
5
PBT
3
16
-1
-4
13
11
15
Tax %
50%
25%
161%
23%
19%
30%
—
Net Profit
1
12
-2
-5
11
8
11
EPS (₹)
-0.56
8.44
-8.05
-10.61
12.69
3.98
5.78
Div. Payout %
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
5
5
6
6
6
6
Reserves
49
55
63
57
65
67
Borrowings
21
23
17
22
8
9
Other Liabilities
62
62
66
76
70
85
Total Liabilities
136
144
152
161
148
167
Fixed Assets
71
68
85
87
74
71
CWIP
0
9
0
0
1
4
Investments
2
0
0
3
0
12
Other Assets
63
66
67
71
73
81
Total Assets
136
144
152
161
148
167
Figures in ₹ Crores

Cash Flow

Particulars Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0
18
-9
1
-4
14
Investing
0
-22
1
-7
20
-15
Financing
0
0
6
6
-16
0
Net Cash Flow
0
-3
-2
0
0
0
Free Cash Flow
0
9
-21
-6
11
11
CFO/EBITDA
0
128
-185
232
-20
118
Figures in ₹ Crores

Ratios

Particulars Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
88
39
72
70
85
52
Inventory Days
344
166
281
227
230
250
Days Payable
182
38
91
112
79
110
Cash Conversion Cycle
250
167
262
185
236
192
Working Capital Days
112
61
113
97
140
106
ROCE %
—
15%
1%
-2%
4%
9%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Makers Laboratories insights

67 extracted metrics + investor summaries across FY07–FY27.

Shareholding Pattern

DIIs0.39%Promot.61.27%Others6.87%Public31.47%As ofSep 2026

Documents

Frequently Asked Questions about Makers Laboratories

What does Makers Laboratories Ltd do?
Incorporated in 1984, Makers Laboratories Ltd manufactures and markets around 200 pharma formulations.[1]
Where is Makers Laboratories Ltd (MAKERSL) listed?
Makers Laboratories Ltd trades as MAKERSL on the NSE and under code 506919 on the BSE.
Which sector does Makers Laboratories Ltd belong to?
Makers Laboratories Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Makers Laboratories Ltd?
Makers Laboratories Ltd has a market capitalisation of ₹111.52 Cr as of 29 Oct 2026, which places it in the Small Cap band.
What is the 52-week high and low of Makers Laboratories Ltd?
Over the last 52 weeks Makers Laboratories Ltd has traded between ₹109 and ₹236 as of 29 Oct 2026.
What is the Return on Equity (ROE) of Makers Laboratories Ltd?
Makers Laboratories Ltd reported a return on equity of 6.42%. Its debt-to-equity ratio is 0.12.

Company Information

Incorporated in 1984, Makers Laboratories Ltd manufactures and markets around 200 pharma formulations.[1]

Website makerslabs.com
Listed 2026-08-17
Face Value ₹ 10
Shares Outstanding 59,00,376

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/506919.md for Makers Laboratories Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month